The cardiovascular and pharmacokinetic profile of dofetilide in conscious telemetered beagle dogs and cynomolgus monkeys

British Journal of Pharmacology

Volumn 154, Issue 7, 2008, Pages 1457-1464

  Haushalter, T M ^a   Friedrichs, G S ^a   Reynolds, D L ^a   Barecki Roach, M ^a   Pastino, G ^a   Hayes, R ^a   Bass, A S ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Arrhythmias; Beagle dogs; Cardiovascular; Cynomolgus monkeys; Dofetilide; Pharmacokinetics; QT c prolongation; Safety pharmacology; Telemetry; Torsades de pointes

Indexed keywords

DOFETILIDE;

ANIMAL EXPERIMENT; ARTERIAL PRESSURE; ARTICLE; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; ELECTROCARDIOGRAM; HEART RATE; HEART RIGHT BUNDLE BRANCH BLOCK; HEART VENTRICLE EXTRASYSTOLE; MALE; MONKEY; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL; TELEMETRY;

ADMINISTRATION, ORAL; ANIMALS; ANTI-ARRHYTHMIA AGENTS; BLOOD PRESSURE; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; HEART RATE; HUMANS; LONG QT SYNDROME; MACACA FASCICULARIS; MALE; MODELS, ANIMAL; PHENETHYLAMINES; SPECIES SPECIFICITY; SULFONAMIDES; TELEMETRY;

EID: 48149097711     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.275     Document Type: Article

References (27)

1. Abel S, Nichols DJ, Brearley CJ, Eve MD (2000). Effect of cimedtidine and ranitidine on pharmacokinetics and pharmacodynamics of a single dose of dofetilide. Br J Clin Pharmacol 49: 64-71.
2. Allen MJ, Nichols NJ, Oliver SD (2000). The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing. Br J Clin Pharmacol 50: 247-253.
3. Anon (2001). ICH S7A Safety pharmacology studies for human pharmaceuticals, implemented by MHLW, CPMP, FDA. Federal Register 66: 36791-36792.
4. Anon (2005). ICHS7B Guidance on safety pharmacology studies for assessing the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. http://www.fda.gov/cder/guidance/index.htm.
5. Belardinelli L, Antzelevitch C, Vos MA (2003). Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci 24: 619-625.
6. Cubeddu LX (2003). QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs. Am J Ther 10: 452-457.
7. Crumb W, Cavero I (1999). QT Interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development. PSTT 2: 270-280.
8. Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C (2000). Effect of a single oral dose of moxifloxacin (400 and 800 mg) on ventricular repolarization in healthy subjects. Clin Pharmacol Ther 68: 658-666.
9. Fermini B, Fossa AA (2003). The impact of drug-induced QT interval prolongation on drug discovery and development. Nat Rev 2: 439-447.
10. Friedrichs GS, Patmore L, Bass A (2005). Non-clinical evaluation of ventricular repolarization (ICH S7B): results of an interim survey of international pharmaceutical companies. J Pharmacol Toxicol Methods 52: 6-11.
11. Funck-Bretano C, Jaillon P (1993). Rate-corrected QT interval, techniques and limitations. Am J Cardiol 72: 17B-22B.
12. LeCoz F, Funck-Brentano C, Morell T, Ghadanfar MM, Jaillan P (1995). Pharmacokinetics and pharmacodynamics modeling of the effects of oral and intravenous administration of dofetilide on ventricular repolarization. Clin Pharmacol Ther 57: 533-542.
13. Lullmann H, Timmermans PB, Ziegler A (1979). Accumulation of drugs by resting or beating cardiac tissue. Eur J Pharmacol 60: 277-285.
14. c prolongation and proarrhythmia in the adult medical intensive care unit. Crit Care Med 32 (Suppl): 154A.
15. Olsen KM (2005). Pharmacologic agents associated with QT interval prolongation. J Family Pract (Suppl): S8-S14.
16. c. Distinguishing a drug effect from spontaneous variability. Am Heart J 131: 472-480.
17. Rasmussen HS, Allen MJ, Blackburn KJ, Buteus GS, Dalrymple HW (1992). Dofetilide, a novel class III antiarrhythmic agent. J Cardiovasc Pharmacol 20 (Suppl 2): S96-S105.
18. Schaffer D, Singer S, Korvick J, Honig P (2002). Concomitant risk factors in reports of torsades de pointes associated with macrolide use. Review of the United States Food and Drug Administration Adverse Event Reporting System. Clin Infect Dis 35: 197-200.
19. Scheffe H (1959). The Analysis of Variance. John Wiley & Sons Inc.: New York.
20. Schoenwald RD (2002). Pharmacokinetics in Drug Discovery and Development. CRC Press: Boca Raton, FL, USA, pp 5-10.
21. Smith DA, Rasmussen HS, Stopher DA, Walker DK (1992). Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man. Xenobiotica 22: 709-719.
22. Stanat SJ, Carlton CG, Crumb Jr WJ, Agrawal KC, Clarkson CW (2003). Characterization of the inhibitory effects of erythromycin and clarithromycin on the HERG potassium channel. Mol Cell Biochem 254: 1-7.
23. Tham TCK, MacLennan BA, Burke MT, Harron DWG (1993). Pharmacodynamics and pharmacokinetics of the class III antiarrhythmic agent dofetilide (UK-68798) in humans. J Cardiovasc Pharmacol 21: 507-512.
24. c-interval prolongation associated with slow intravenous erythromycin lacrobionate infusions in critically ill patients: a prospective evaluation and review of literature. Pharmacotherapy 16: 663-674.
25. Walker DK, Alabaster CT, Congreve GS, Hargreaves MB, Hyland R, Jones BC et al. (1996a). Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. Drug Metab Disp 24: 447-455.
26. Walker DK, Beaumont KC, Stopher DA, Smith DA (1996b). Pharmacokinetics of a series of bis (methane sulphonamide-alkyl) amines in the beagle dog. Xenobiotica 26: 1101-1111.
27. Watkins R, Pula K, Chintala M, Bass AS (2003). (Abstract) Dofetilide prolongs QT interval and induces torsades de pointes in conscious telemetered monkeys. Cardiovascular Risk Assessment Workshop. International Life Sciences Institute Health, Environmental Sciences Institute, Arlington, VA June.